Skip to content
PeptideFactSheets

Peptide · Fact sheet

Kisspeptin

Also known as kisspeptin-54 · kisspeptin-10 · metastin

Kisspeptin can activate reproductive-hormone signaling in people and has been studied as an egg-maturation trigger in IVF research. It is not FDA approved for fertility, libido, testosterone, mood, or other consumer uses.

In clinical trialsEarly human evidence
Hormones & sexual health

What is Kisspeptin?

Kisspeptins are related peptides made from the KISS1 protein. They stimulate gonadotropin-releasing hormone neurons and sit near the top of the reproductive hormone cascade.

Kisspeptin-54 and kisspeptin-10 differ in length and exposure; findings from one formulation or setting should not be silently applied to another.

Benefits people look for

Human studies have examined hormone release, puberty biology, IVF egg maturation, sexual and emotional brain processing, and reproductive disorders.

The pathway is compelling, but changing a hormone signal is not the same as proving better fertility, sexual function, mood, or long-term health.

What the evidence supports

  • A completed Phase 2 program showed that kisspeptin-54 could produce mature eggs in selected people undergoing IVF.
  • Human crossover studies demonstrate short-term effects on luteinizing hormone and some brain-response measures, not proven fertility or mental-health benefits.
All research areas
  • Egg maturation during IVF
  • Reproductive hormone release
  • Hypothalamic amenorrhea and other reproductive disorders
  • Sexual and emotional brain processing
  • Triggering egg maturation in selected IVF settings
  • Diagnosing or treating reproductive hormone disorders
  • Neuroendocrine and behavioral research

Anecdotal reports & lived experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.

No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.

We do not fill this gap with unsourced testimonials or estimated success rates.

Side effects & risks

  • Short-term research has not established a complete safety profile for repeated or broader use.
  • FDA identifies potential immune reactions, peptide impurities, and limited route-specific safety information for compounded kisspeptin-10.
  • Changing reproductive-hormone signaling may create different risks across sex, age, pregnancy status, and endocrine conditions.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research: how strong is it?

Early human evidence

Controlled human studies confirm reproductive-hormone effects and show that kisspeptin-54 can trigger egg maturation in selected IVF research populations. Larger comparative trials and long-term outcomes remain limited.

Selected research to read

FDA approval & research status

Kisspeptin has no FDA-approved drug product. Human research includes completed Phase 2 IVF studies, while FDA has described limited safety information and potential peptide-quality concerns for compounded kisspeptin-10.

No FDA-approved use is documented in the records summarized on this page.

Early to mid-stage reproductive research

Kisspeptin has human Phase 2 research in IVF-related triggering, but it has no FDA-approved product or broad reproductive, mood, or wellness indication.

This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.

What we still don’t know

  • Whether it improves live-birth outcomes compared with established IVF approaches
  • Long-term reproductive and metabolic safety
  • Which formulation and patient groups, if any, offer a favorable benefit-risk balance
  • Whether brain-imaging or hormone changes translate into meaningful daily-life outcomes

The takeaway

Kisspeptin is one of the more credible experimental reproductive peptides because human physiology and IVF studies exist. It remains investigational, and hormone changes are not a shortcut to proven fertility or sexual benefits.

Sources & further reading

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. 1
    clinical trialsClinicalTrials.gov: kisspeptin in IVF

    Completed Phase 2 study with public results on egg maturation during IVF.

  2. 2
    pubmedKisspeptin-54 egg-maturation study

    Human study of kisspeptin-54 as an egg-maturation trigger.

  3. 3
    pubmedRandomized study of sexual and emotional brain processing

    Controlled human mechanistic study that does not establish a therapeutic benefit.

  4. 4
    fdaFDA: safety risks for selected compounded bulk substances

    FDA's current substance-specific summary of evidence gaps and potential safety risks.

How we assess sources · Suggest a correction